Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
28 Mar 24
8-K
Other Events
19 Mar 24
EFFECT
Notice of effectiveness
18 Mar 24
424B3
Prospectus supplement
15 Mar 24
S-8
Registration of securities for employees
6 Mar 24
S-1/A
IPO registration (amended)
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
D
Exempt offering of security
14 Feb 24
S-1
IPO registration
2 Feb 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
424B5
Prospectus supplement for primary offering
30 Jan 24
8-K
Other Events
22 Jan 24
8-K
Material Modifications to Rights of Security Holders
10 Jan 24
DEFA14A
Additional proxy soliciting materials
2 Jan 24
EFFECT
Notice of effectiveness
28 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
CORRESP
Correspondence with SEC
21 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
DEFA14A
Additional proxy soliciting materials
20 Dec 23
DEFA14A
Additional proxy soliciting materials
20 Dec 23
S-3
Shelf registration
18 Dec 23
DEF 14A
Definitive proxy
15 Dec 23
PRE 14A
Preliminary proxy
4 Dec 23
8-K
Seelos Therapeutics Announces Closing of Public Offering
1 Dec 23
8-K
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
30 Nov 23
424B5
Prospectus supplement for primary offering
30 Nov 23
424B5
Prospectus supplement for primary offering
28 Nov 23
424B3
Prospectus supplement
28 Nov 23
8-K
Material Modifications to Rights of Security Holders
28 Nov 23
8-K
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
24 Nov 23
8-K
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
24 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Nov 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
EFFECT
Notice of effectiveness
2 Oct 23
424B3
Prospectus supplement
29 Sep 23
CORRESP
Correspondence with SEC
26 Sep 23
8-K
Entry into a Material Definitive Agreement
25 Sep 23
424B5
Prospectus supplement for primary offering
25 Sep 23
Latest ownership filings
4
Michael Joseph Golembiewski
1 Mar 24
SC 13G
Lind Global Fund II LP
6 Feb 24
4
Raj Mehra
17 Jan 24
4
Michael Joseph Golembiewski
17 Jan 24
4
Richard W Pascoe
8 Jan 24
4
MARGARET DALESANDRO
8 Jan 24
4
Brian Lian
8 Jan 24
4
Daniel J. O'Connor
8 Jan 24
4
Michael Joseph Golembiewski
1 Dec 23
4
Raj Mehra
1 Dec 23
4
Michael Joseph Golembiewski
1 Sep 23
4
Raj Mehra
31 Mar 23
4
Michael Joseph Golembiewski
31 Mar 23
4
Michael Joseph Golembiewski
2 Mar 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
4
Richard W Pascoe
5 Jan 23
4
Daniel J. O'Connor
5 Jan 23
4
MARGARET DALESANDRO
5 Jan 23
4
Brian Lian
5 Jan 23
SC 13G
BlackRock Inc.
8 Jul 22
4
Daniel J. O'Connor
2 Jun 22
4
MARGARET DALESANDRO
27 May 22
4
Raj Mehra
31 Mar 22
4
Michael Joseph Golembiewski
4 Mar 22
SC 13G/A
VANGUARD GROUP INC
10 Feb 22
SC 13G
BlackRock Inc.
4 Feb 22
4
Raj Mehra
11 Jan 22
4
Michael Joseph Golembiewski
11 Jan 22
4
Richard W Pascoe
6 Jan 22
4
Daniel J. O'Connor
6 Jan 22
4
MARGARET DALESANDRO
6 Jan 22
4
Brian Lian
6 Jan 22
4
MARGARET DALESANDRO
2 Sep 21
3
MARGARET DALESANDRO
2 Sep 21
3
Michael Joseph Golembiewski
2 Sep 21
4
Raj Mehra
17 Mar 21
SC 13G
VANGUARD GROUP INC
10 Feb 21
SC 13G/A
LIGAND PHARMACEUTICALS INC
15 Jan 21
SC 13G/A
Phoenixus AG
11 Jan 21
4
Judith Dunn
8 Jan 21